Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration

Journal of Clinical Microbiology

Volumn 51, Issue 3, 2013, Pages 849-856

  Fite, Alemu ^a   Macfarlane, Sandra ^a   Furrie, Elizabeth ^a   Bahrami, Bahram ^a   Cummings, John H ^a   Steinke, Douglas T ^b   MacFarlane, George T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BIOFILM; CLINICAL ARTICLE; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM PERFRINGENS; COLON MUCOSA; CONTROLLED STUDY; DESULFOVIBRIO; DISEASE DURATION; DISEASE SEVERITY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; EUBACTERIUM; EUBACTERIUM RECTALE; FEMALE; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LONGITUDINAL STUDY; MALE; MICROBIAL COMMUNITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RUMINOCOCCUS ALBUS; ULCERATIVE COLITIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIODIVERSITY; BIOPSY; COLITIS, ULCERATIVE; FEMALE; HUMANS; INTESTINAL MUCOSA; LONGITUDINAL STUDIES; MALE; METAGENOME; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84874057008     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02574-12     Document Type: Article

References (57)

1. Croucher SC, Houston AP, Bayliss CE, Turner RJ. 1983. Bacterial populations associated with different regions of the human colon wall. Appl. Environ. Microbiol. 45:1025-1033.
2. Macfarlane S, Bahrami B, Macfarlane GT. 2011. Mucosal biofilm communities in the human intestinal tract. Adv. Appl. Microbiol. 75:111-143.
3. Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. 2004. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin. Infect. Dis. 38:1690-1699.
4. Poxton IR, Brown R, Sawyerr A, Ferguson A. 1997. Mucosa-associated bacterial flora of the human colon. J. Med. Microbiol. 46:85-91.
5. Zoetendal G, Von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. 2002. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 68:3401-3407.
6. Ahmed S, Macfarlane GT, Fite A, McBain AJ, Gilbert P, Macfarlane S. 2007. Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl. Environ. Microbiol. 73:7435-7442.
7. Carter MJ, Lobo AJ, Travis SP. 2004. Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl 5):V1-V16. doi:10 .1136/gut.2004.043372.
8. Cohen MB, Giannella RA. 1991. Bacterial infections: pathophysiology, clinical features and treatment, p 395-428. In Phillips SF, Pemberton JH, Shorter RG (ed), The large intestine: physiology, pathophysiology and disease. Raven Press, New York, NY.
9. Macfarlane GT, Gibson GR. 1995. Bacterial infections and diarrhea, p 201-206. In Gibson GR, Macfarlane GT (ed), Human colonic bacteria: role in nutrition, physiology and pathology. CRC Press, Boca Raton, FL.
10. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez- Sueiro JL, Balish E, Hammer RE. 1994. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180:2359-2364.
11. Victor RJ, Kirsner JB, Palmer W. 1950. Failure to induce ulcerative colitis experimentally with filtrates of feces and rectal mucosa. Gastroenterology 14:398-400.
12. Cummings JH, Macfarlane GT, Macfarlane S. 2003. Intestinal bacteria and ulcerative colitis. Curr. Issues Intest. Microbiol. 4:9-20.
13. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefson L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. Science 308:1635-1638.
14. Lepage P, Seksik P, Sutren M, de la Cochetiere MF, Marteau P, Dore J. 2005. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis. 11:473-480.
15. Macfarlane S, Hopkins MJ, Macfarlane GT. 2000. Bacterial growth and metabolism on surfaces in the large intestine. Microb. Ecol. Health Dis. 2:64-72.
16. Fite A, Macfarlane GT, Cummings JH, Hopkins MJ, Kong SC, Furrie E, Macfarlane S. 2004. Identification and quantitation of mucosal and faecal desulfovibrios using real-time PCR. Gut 53:523-529.
17. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. 2006. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohńs disease and ulcerative colitis patients. J. Med. Microbiol. 55: 1141-1149.
18. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. 2005. Spatial organisation and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43:3380-3389.
19. Zhang M, Liu B, Zhang Y, Wei H, Lei Y, Zhao L. 2007. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J. Clin. Microbiol. 45:496-500.
20. Ott SJ, Plamondon S, Hart A, Begun A, Rehman A, Kamm MA, Screiber S. 2008. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J. Clin. Microbiol. 46:3510-3513.
21. Ott SJ, Musfeldt M, Wendereroth DF, Hampe J, Brant O, Fosch UR, Timmis KN, Schrieber S. 2004. Reduction in diversity of the colonic mucosa associated microflora in patients with active inflammatory bowel disease. Gut 53:685-693.
22. Walmsley RS, Ayres RCS, Pounder RE. 1998. A simple clinical colitis activity index. Gut 43:29-32.
23. Baron JH, Connell AM, Lennard-Jones JE. 1964. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. i:89-92.
24. Bartosch S, Fite A, Macfarlane GT, McMurdo ME. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl. Environ. Microbiol. 70: 3575-3581.
25. Daube G, China B, Simon P, Huala K, Mainil J. 1994. Typing of Clostridium perfringens by in vitro amplification of toxin genes. J. Appl. Bacteriol. 77:650-655.
26. Wang R, Cao W, Cerniglia CE. 1996. PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Appl. Environ. Microbiol. 62:1242-1247.
27. Riggio MP, Lennon A. 2002. Development of a PCR assay specific for Peptostreptococcus anaerobius. J. Med. Microbiol. 51:1097-1101.
28. Malinen E, Kassinen A, Rinttila T, Palva A. 2003. Comparison of real-time PCR with SYBR green I or 5=-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. Microbiology 149:269-277.
29. Kok RG, de Waal A, Schut F, Welling GW, Weenk G, Hellingwerf KJ. 1996. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl. Environ. Microbiol. 62:3668-3672.
30. Bernard AE, Field KG. 2000. Identification of nonpoint sources of fecal pollution in coastal waters by using host-specific 16S ribosomal DNA genetic markers from fecal anaerobes. Appl. Environ. Microbiol. 66:1587-1594.
31. Huijsdens XW, Linskens RK, Mak M, Meuwissen SG, Vandenbroucke- Grauls CM, Savelkoul PH. 2002. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J. Clin. Microbiol. 40:4423-4427.
32. Schwiertz A, Lehmann U, Jacobisch G, Blaut M. 2002. Influence of resistant starch on the SCFA production and cell counts of butyrateproducing Eubacterium spp. in the human intestine. J. Appl. Microbiol. 93:157-162.
33. Nadkarni MA, Martin FE, Jacques N, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148:257-266.
34. Macfarlane S, Macfarlane GT. 2004. Bacterial diversity in the large intestine. Adv. Appl. Microbiol. 54:261-289.
35. Pathmakanthan S, Thornley JP, Hawkey CJ. 1999. Mucosally associated bacterial flora of the human colon: quantitative and species specific differences between normal and inflamed colonic biopsies. Microb. Ecol. Health Dis. 11:169-174.
36. Sartor RB. 2008. Microbial influences in inflammatory bowel disease. Gastroenterology 134:577-594.
37. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening- Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54.
38. Schultsz C, van den Berg F, Ten Kate FW, Tytgat GN, Dankert J. 1999. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117:1089-1097.
39. Manichanh C, Borruel N, Casellas F, Guarner F. 2012. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9:599-608.
40. Ruseler van Embden JGH, Schouten WR, van Lieshout LMC
41. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. 2005. Molecular characterisation of rectal-mucosa bacterial flora in inflammatory bowel disease. Inflamm. Bowel Dis. 11:481-487.
42. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Kohler H. 2010. Microbiota in pediatric inflammatory bowel disease. J. Pediatr. 157:240-244.
43. Furrie E, Macfarlane S, Cummings JH, Macfarlane GT. 2004. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohńs disease differentially activate the innate immune response. Gut 53:91-99.
44. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, ÓNeil DA, Macfarlane GT. 2005. Synbiotic therapy significantly reduces molecular markers of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 54:242-249.
45. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. 2010. Clinical trial: the microbiological and immunological effects of synbiotic consumption-a randomized double-blind placebo-controlled study in active Crohńs disease. Aliment. Pharmacol. Ther. 32:872-883.
46. Zoetendal EG, Akkermans AD, De Vos WM. 1998. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl. Environ. Microbiol. 64:3854-3859.
47. Gibson GR, Cummings JH, Macfarlane GT. 1991. Growth and activities of sulphate-reducing bacteria in gut contents from healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 86:103-112.
48. Loubinoux J, Bronowicji J-P, Pereira IAC, Moungenel JL, Faou AE. 2002. Sulfate-reducing bacteria in human feces and their association with inflammatory diseases. FEMS Microbiol. Ecol. 40:107-112.
49. Pitcher MCL, Beatty ER, Harris RM, Waring RH, Cummings JH. 1998. Sulfur metabolism in ulcerative colitis. Investigation of detoxification enzymes in peripheral blood. Dig. Dis. Sci. 43:2080-2085.
50. Roediger WEW, Duncan A, Kapaniris O, Millard S. 1993. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 104:802-809.
51. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ. 1995. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36:897-901.
52. Tvede M, Bondesen S, Nielsen OH, Rasmussen SN. 1983. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease. Scand. J. Gastroenterol. 18:783-789.
53. Bamba T, Matsuda H, Endo M, Fugiyama Y. 1995. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J. Gastroenterol. 30:45-47.
54. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. 2000. Characterization of antibody responses against rectal mucosaassociated bacterial flora in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 15:61-68.
55. Onderdonk AB, Franklin ML, Cisneros RL. 1981. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect. Immun. 32:225-231.
56. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11:853-858.
57. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635-639.